In the limited number of lung cancer cell lines that we studied the response to co-inhibition by PI3K inhibitors and rapamycin or to the dual inhibitor, NVP-BEZ235, was independent of wild-type or mutant EGFR status. This evidence concerns the gene EGFR and lung cancer.